GOGL – Transition of Chief Financial Officer
Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (“Golden Ocean” or the “Company“) today announced that Mr. Per Heiberg, Chief Financial Officer of Golden Ocean Management AS, has submitted his notice of resignation. Mr. Heiberg has held this position since April 2016 and has worked for the company in various capacities since July 2005.
The Company also announced that Peder Simonsen has been appointed as the new CFO of Golden Ocean Management AS. Mr. Simonsen was most recently the Chief Financial Officer and Interim Chief Executive Officer of Avance Gas AS. Prior to joining Avance Gas AS in 2014, he was First Vice President at Nordea Bank Norge ASA, where he worked with numerous large shipping and offshore companies.
Mr. Ulrik Andersen, Chief Executive Officer of Golden Ocean Management AS commented: "Per has made a huge contribution to the growth and success of Golden Ocean, and we wish him the very best in his future. Per is departing the Company on the best of terms and will remain with the Company until such time as a smooth transition of his responsibilities has been completed. We are delighted that Peder Simonsen is joining our team. He is a proven CFO with a superior track record of delivering results and creating value and is a strong addition to our executive management team.”
Mr. Heiberg commented: “I have had the pleasure to work for Golden Ocean and contribute to the Company’s growth over the last 15 years and through most of its history. That has been a fantastic journey, and I will take with me many fond memories of our collective accomplishments. I am pleased to be departing the Company at time when it is solid financially and well positioned for the future.”
Mr. Simonsen commented: “I am pleased to join Golden Ocean, one of the world’s largest dry bulk companies. I hope to help the Company build upon its strong track record of success at a time when the dry bulk market has turned the corner and should benefit from recovering demand and a swift slowdown in fleet growth. The Company has a well-managed balance sheet, which we expect to enhance further in the coming year. “
About Golden Ocean
Golden Ocean, a leading dry bulk shipping company, owns or controls a modern fleet of 78 vessels with an average age of approximately 6 years. The Company is one of the largest publicly listed owners of Capesize vessels and has a leading position in the ice class Panamax vessel niche. Golden Ocean is listed on the NASDAQ and Oslo Stock Exchange under the symbol ‘GOGL’.
September 07, 2020
The Board of Directors
Golden Ocean Group Limited
Hamilton, Bermuda
For further queries, please contact:
Ulrik Andersen: Chief Executive Officer, Golden Ocean Management AS
+47 22 01 73 53
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease1.12.2020 22:01:00 CET | Press release
Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737. The drug candidate or placebo will be administered for 52 weeks in up to 60 ADPKD patients with rapidly progressing disease. Patients will be randomized in a 2:1 ratio of treatment to placebo. Primary objectives of the trial are to assess the growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability. Secondary measures include renal function, pharmacokinetics, and pharmacodynamics. Recruitment for the MANGROVE trial is planned in 7 countries in Europe. GLPG2737 is a CFTR1 inhibitor which was shown to be well tolerated by patients in previous clinical trials. It is hypothesi
REC Silicon – Cancellation of subsequent offering1.12.2020 20:13:46 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Lysaker, 1 December 2020 Reference is made to the stock exchange announcements by REC Silicon ASA (the "Company") on 14 October 2020 and 15 October 2020 regarding the successful completion of a private placement raising gross proceeds of approximately NOK 1,000 million (the "Private Placement") and a potential subsequent offering (the "Subsequent Offering") of up to 18,518,518 new shares directed towards shareholders of the Company as of 14 October 2020 who were not allocated shares in the Private Placement. The Company has decided not to initiate the Subsequent Offering. The background for the cancellation is that the Company's shares have over time traded on the Oslo Stock Exchange, with significant trading volume, at prices below the subscription pric
Bombardier and Alstom Confirm Receipt of All Necessary Regulatory Approvals to Complete Bombardier Transportation Sale to Alstom1.12.2020 18:24:09 CET | Press release
MONTRÉAL, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) and Alstom announced today that all necessary regulatory approvals required to complete the sale of Bombardier Transportation to Alstom have been received. Bombardier and Alstom now expect the transaction to close on January 29, 2021. About Bombardier With over 52,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are availab
FDA approves Xolair® (omalizumab) for adults with nasal polyps1.12.2020 18:07:00 CET | Press release
Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammationXolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key d
Tecan raises forecast for the full year of 2020 based on continued extraordinary demand for COVID-19 related products1.12.2020 18:02:00 CET | Press release
Sales growth now expected to be in the low to mid-teens percentage range in local currenciesReported EBITDA margin now forecasted above 20.5% of sales Männedorf, Switzerland, 1 December, 2020 – Based on the strong business performance year to date, as well as on the high order backlog and the continued elevated demand for COVID-19 related products, the Tecan Group (SIX Swiss Exchange: TECN) once again raised its outlook for full-year sales and reported EBITDA margin. These updated projections continue to be based on the assumptions that also for the remainder of the year supply chains and freight logistics remain undisrupted and all production sites stay fully operational. Based on continued strong demand for a number of product lines to help in the global fight against the coronavirus pandemic, Tecan now forecasts sales growth for full-year 2020 to be in the low to mid-teens percentage range in local currencies (latest guidance from August 12, 2020: “high single-digit percentage range
Touax: Successful asset refinancing - Containers Business1.12.2020 17:45:00 CET | Press release
PRESS RELEASE Paris, December 1, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Successful asset refinancing - Containers Business Touax announces today that it has successfully refinanced asset-backed facilities of its Container division for a total of US$ 75 million, versus US$ 60 million previously, combining a Term Loan of US$ 37 million and a Revolving Credit Facility (RCF) of US$ 38 million with a two-year maturity. The documentation provides for an accordion option, allowing the line to be scaled up to US$ 85 million, to support growth. This operation allows the refinancing of the existing portfolio of assets as well as the financing of future investments. Touax Container Asset Finance Ltd will thus continue to invest for its development, particularly in the purchase of equipment for leasing purpose. Financing is granted by ABN AMRO Bank N.V., ING Belgium SA / NV and NIBC Bank N.V. Touax was advised by Stephenson Harwood (Legal Counsel). “We ar